Psychosis in Elderly Patients: Classification and Pharmacotherapy

Psychosis in elderly patients is a growing clinical concern because psychotic symptoms most frequently occur as noncognitive manifestations of Alzheimer’s disease, as side effects of drug therapy for Parkinson’s disease, or as the primary abnormalities in schizophrenia, and the clinical characteristics of psychosis are distinct for each. In planning antipsychotic pharmacotherapy for elderly patients, age-related pharmacokinetic changes, polypharmacy for comorbid diseases, and concerns about the underlying conditions responsible for the psychotic symptoms must be considered. Traditional antipsychotic agents bind to dopamine receptors and effectively relieve positive schizophrenic symptoms but frequently cause tardive dyskinesia and other extrapyramidal symptoms, a problem for elderly patients, particularly for those with Parkinson’s disease. Atypical antipsychotics bind to dopamine and serotonin receptors, relieving both positive and negative symptoms, and are less likely to cause extrapyramidal symptoms. The authors review common diagnostics associated with psychosis in the elderly and clinical guidelines to selecting antipsychotic pharmacotherapy.

[1]  Robert Perry,et al.  Dementia with Lewy Bodies , 2007, Seminars in neurology.

[2]  W. Hazzard,et al.  Principles of Geriatric Medicine and Gerontology , 2003 .

[3]  C. d’Souza,et al.  MANAGEMENT OF PSYCHOSIS IN PARKINSON'S DISEASE , 2003, International journal of clinical practice.

[4]  Joyce R. Borkin,et al.  The relationship between cognitive dysfunction and coping abilities in schizophrenia , 2002, Schizophrenia Research.

[5]  C. Fuchs,et al.  Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition. , 2002, The American journal of psychiatry.

[6]  Jonathan M. Meyer A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year. , 2002, The Journal of clinical psychiatry.

[7]  R. Roos,et al.  Use of antipsychotics in Parkinson's disease in daily practice , 2002 .

[8]  C. Caley,et al.  Ziprasidone: The Fifth Atypical Antipsychotic , 2002, The Annals of pharmacotherapy.

[9]  S. Wisniewski,et al.  Apolipoprotein E and Alpha-1-Antichymotrypsin Genotypes Do Not Predict Time to Psychosis in Alzheimer's Disease , 2002, Journal of geriatric psychiatry and neurology.

[10]  S. Caroff,et al.  Movement disorders associated with atypical antipsychotic drugs. , 2002, The Journal of clinical psychiatry.

[11]  B. Pollock,et al.  Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. , 2002, The American journal of psychiatry.

[12]  Y. Barak No weight gain among elderly schizophrenia patients after 1 year of risperidone treatment. , 2002, The Journal of clinical psychiatry.

[13]  G. Keating,et al.  Ziprasidone , 2012, Drugs.

[14]  John M. Davis,et al.  Clinical profile of an atypical antipsychotic: risperidone. , 2002, Schizophrenia bulletin.

[15]  Philip D. Harvey Cognitive impairment in elderly patients with schizophrenia: age related changes , 2001, International journal of geriatric psychiatry.

[16]  P. Tariot,et al.  A Randomized, Double‐Blind, Placebo‐Controlled Study of the Efficacy and Safety of Donepezil in Patients with Alzheimer's Disease in the Nursing Home Setting , 2001, Journal of the American Geriatrics Society.

[17]  A H Glassman,et al.  Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. , 2001, The American journal of psychiatry.

[18]  R. Manni,et al.  Hallucinations, REM sleep, and Parkinson’s disease: A medical hypothesis , 2001, Neurology.

[19]  D. Sultzer,et al.  Does Behavioral Improvement with Haloperidol or Trazodone Treatment Depend on Psychosis or Mood Symptoms in Patients with Dementia? , 2001, Journal of the American Geriatrics Society.

[20]  L. Beckett,et al.  Annual Incidence of Alzheimer Disease in the United States Projected to the Years 2000 Through 2050 , 2001, Alzheimer disease and associated disorders.

[21]  P. Goodnick Ziprasidone: profile on safety , 2001, Expert opinion on pharmacotherapy.

[22]  R. Goetz,et al.  Weight gain and antipsychotic medication: differences between antipsychotic-free and treatment periods. , 2001, The Journal of clinical psychiatry.

[23]  S. Kuzuhara Drug-induced psychotic symptoms in Parkinson's disease. Problems, management and dilemma , 2001, Journal of Neurology.

[24]  E. Wolters,et al.  Intrinsic and extrinsic psychosis in Parkinson's disease , 2001, Journal of Neurology.

[25]  H. Feldman,et al.  A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease , 2001, Neurology.

[26]  Anne W. Schmidt,et al.  Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. , 2001, European journal of pharmacology.

[27]  S. Targum Treating Psychotic Symptoms in Elderly Patients. , 2001, Primary care companion to the Journal of clinical psychiatry.

[28]  S. Factor,et al.  Parkinson’s disease: The treatment of drug-induced hallucinations and psychosis , 2001, Current neurology and neuroscience reports.

[29]  I. McDowell,et al.  Alzheimer’s disease: Insights from epidemiology , 2001, Aging.

[30]  L. Tune,et al.  Neuroleptic treatment of late-life schizophrenia. , 2001, Harvard review of psychiatry.

[31]  M. Byerly,et al.  Antipsychotic Medications and the Elderly , 2001, Drugs & aging.

[32]  S. Leucht Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. , 2001, Neurology.

[33]  B. Green Focus on ziprasidone. , 2001, Current medical research and opinion.

[34]  D. Daniel Antipsychotic treatment of psychosis and agitation in the elderly. , 2000, The Journal of clinical psychiatry.

[35]  D. Jeste,et al.  Psychosis of Alzheimer's disease and related dementias. Diagnostic criteria for a distinct syndrome. , 2000, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[36]  White matter hyperintensity volume in late‐onset and early‐onset schizophrenia , 2000, International journal of geriatric psychiatry.

[37]  N. Andreasen,et al.  Clinical features characterizing young-onset and intermediate-onset schizophrenia. , 2000, The Journal of neuropsychiatry and clinical neurosciences.

[38]  M. Trabucchi,et al.  Incidence of and risk factors for hallucinations and delusions in patients with probable AD , 2000, Neurology.

[39]  A. Bagnall,et al.  Ziprasidone for schizophrenia and severe mental illness. , 2000, The Cochrane database of systematic reviews.

[40]  R. Tamura,et al.  Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. , 2000, Archives of general psychiatry.

[41]  J. Mintzer,et al.  Anticholinergic side-effects of drugs in elderly people , 2000, Journal of the Royal Society of Medicine.

[42]  P. Tariot,et al.  A 5-month, randomized, placebo-controlled trial of galantamine in AD , 2000, Neurology.

[43]  S. Kasper,et al.  Review of quetiapine and its clinical applications in schizophrenia , 2000, Expert opinion on pharmacotherapy.

[44]  D. Jeste Tardive dyskinesia in older patients. , 2000, The Journal of clinical psychiatry.

[45]  S. Targum,et al.  Efficacy of quetiapine in Parkinson's patients with psychosis. , 2000, Journal of clinical psychopharmacology.

[46]  C. Lyketsos,et al.  Delusions and hallucinations in Alzheimer's disease: prevalence and clinical correlates , 2000, International journal of geriatric psychiatry.

[47]  B. Kirkpatrick,et al.  Epidemiology of schizophrenia in northeast Brazil. , 2000, The Journal of nervous and mental disease.

[48]  M. Sajatovic,et al.  Schizophrenia in the Elderly , 2000 .

[49]  P. Masand,et al.  Side effects of antipsychotics in the elderly. , 2000, The Journal of clinical psychiatry.

[50]  D. Jeste,et al.  Conventional vs. newer antipsychotics in elderly patients. , 1999, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[51]  P. Sachdev,et al.  Schizophrenia with onset after age 50 years , 1999, British Journal of Psychiatry.

[52]  J. Cummings,et al.  Quetiapine for the treatment of drug-induced psychosis in Parkinson's disease. , 1999, Movement disorders : official journal of the Movement Disorder Society.

[53]  B. Lawlor,et al.  A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia , 1999, Neurology.

[54]  D. Jeste,et al.  Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. , 1999, The Journal of clinical psychiatry.

[55]  T. Mellman,et al.  Psychotic symptoms in combat-related posttraumatic stress disorder. , 1999, The Journal of clinical psychiatry.

[56]  D. Jeste,et al.  Gender-related clinical differences in older patients with schizophrenia. , 1999, The Journal of clinical psychiatry.

[57]  J. Juncos,et al.  Management of psychotic aspects of Parkinson's disease. , 1999, The Journal of clinical psychiatry.

[58]  G. Stoppe,et al.  Behavioural Problems Associated With Dementia , 1999, Drugs & aging.

[59]  R. Tandon,et al.  The efficacy, safety, and tolerability of antipsychotics in the elderly. , 1999, The Journal of clinical psychiatry.

[60]  A. Riecher-Rössler,et al.  Is schizophrenia a disorder of all ages? A comparison of first episodes and early course across the life-cycle , 1998, Psychological Medicine.

[61]  G. Grossberg,et al.  The treatment of psychosis in late life. , 1998, The Journal of clinical psychiatry.

[62]  Jeste,et al.  Psychoses in Parkinson's Disease. , 1998, Seminars in clinical neuropsychiatry.

[63]  S H Ferris,et al.  Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. , 1997, JAMA.

[64]  L. Beckett,et al.  Psychotic Symptoms and Physically Aggressive Behavior in Alzheimer's Disease , 1997, Journal of the American Geriatrics Society.

[65]  M. Albert,et al.  Predicting time to nursing home care and death in individuals with Alzheimer disease. , 1997, JAMA.

[66]  M. Albert,et al.  The course of psychopathologic features in mild to moderate Alzheimer disease. , 1997, Archives of general psychiatry.

[67]  D. St. Clair Apolipoprotein E gene in Parkinson's disease, Lewy body dementia and Alzheimer's disease. , 1997, Journal of neural transmission. Supplementum.

[68]  S H Ferris,et al.  Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. , 1997, Alzheimer disease and associated disorders.

[69]  J. Cummings,et al.  Longitudinal assessment of symptoms of depression, agitation, and psychosis in 181 patients with Alzheimer's disease. , 1996, The American journal of psychiatry.

[70]  R. Mohs,et al.  Cognitive functioning in late-life schizophrenia: a comparison of elderly schizophrenic patients and patients with Alzheimer's disease. , 1996, The American journal of psychiatry.

[71]  G. Binetti,et al.  Risk of Mortality and Institutionalization in Demented Patients with Delusions , 1996, Journal of geriatric psychiatry and neurology.

[72]  Mrc Psych,et al.  Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop , 1996 .

[73]  Hans Förstl,et al.  Late-onset schizophrenia and late paraphrenia. , 1995, Schizophrenia bulletin.

[74]  L. Schneider,et al.  Extrapyramidal signs and psychiatric symptoms predict faster cognitive decline in Alzheimer's disease. , 1994, Archives of neurology.

[75]  J. Trojanowski,et al.  Elderly patients with schizophrenia exhibit infrequent neurodegenerative lesions , 1994, Neurobiology of Aging.

[76]  P. Tariot,et al.  Mental disorders in the nursing home: another perspective. , 1993, The American journal of psychiatry.

[77]  R. Sandyk,et al.  Late-onset schizophrenia: relationship to awareness of abnormal involuntary movements and tobacco addiction. , 1993, The International journal of neuroscience.

[78]  Late‐onset schizophrenia , 1993 .

[79]  R. Murray,et al.  The epidemiology of late-onset schizophrenia. , 1993, Schizophrenia bulletin.

[80]  D. Jeste,et al.  Cognitive deficits of patients with Alzheimer's disease with and without delusions. , 1992, The American journal of psychiatry.

[81]  G A Chase,et al.  Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease. , 1990, The American journal of psychiatry.

[82]  D. Jeste,et al.  Overview of depression and psychosis in Alzheimer's disease. , 1989, The American journal of psychiatry.

[83]  J. Talbott,et al.  Textbook of Psychiatry , 1988 .

[84]  G. Pearlson,et al.  Late-onset schizophrenia. Studying clinical validity. , 1988, The Psychiatric clinics of North America.

[85]  D. Jeste,et al.  Late-onset schizophrenia: an overview. , 1988, Schizophrenia bulletin.

[86]  S. Zarit,et al.  Subjective burden of husbands and wives as caregivers: a longitudinal study. , 1986, The Gerontologist.

[87]  N. Watson,et al.  Behavioral problems among patients in skilled nursing facilities. , 1984, American journal of public health.

[88]  A. Loranger Sex difference in age at onset of schizophrenia , 1984 .